Advertisement

Topics

Herantis Pharma Oyj: Herantis Pharma announces initiation of Phase 2 study for Lymfactin gene therapy in secondary lymphedema

02:05 EDT 13 Jun 2018 | FinanzNachrichten

Herantis Pharma announces initiation of Phase 2 study for Lymfactin gene therapy in secondary lymphedema Herantis Pharma Plc Company release 13 Jun 2018 at 9:00 am Herantis Pharma Plc ("Herantis")...

Original Article: Herantis Pharma Oyj: Herantis Pharma announces initiation of Phase 2 study for Lymfactin gene therapy in secondary lymphedema

NEXT ARTICLE

More From BioPortfolio on "Herantis Pharma Oyj: Herantis Pharma announces initiation of Phase 2 study for Lymfactin gene therapy in secondary lymphedema"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...